Design of metallocenic drugs.
Studies on structure-activity relationships of organometallic anticancer drugs are reviewed. Three methods for the development of new structures are described. Drug targeting: platinum complexes with oestrophilic ligands were synthesized, and the endocrine and cytostatic effects are discussed. Quantitative structure-activity relationship determination is presented as a rational method for the design of active compounds. The molecular modelling technique is used for the analysis of molecular properties.
D000818:Animals; D000970:Antineoplastic Agents; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D007939:Leukemia L1210 / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D011960:Receptors, Estrogen / Q000378:metabolism; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D011960:Receptors, Estrogen